Verrica Pharmaceuticals(VRCA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results – Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – – Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – – Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H ...